Eos SENOLYTIX to Highlight Next-Generation Mitochondria-Targeted Therapeutics at 17th World Congress on Targeting Mitochondria

* Founder and CEO Kevin Slawin, M.D., to deliver industry keynote on advancing mitochondrial-targeted geropeptide medicine * Eos advancing lead candidate MitoXcel™ geropeptide PTC-2105 toward first-in-human studies for sarcopenia and sarcopenic obesity * Eos anticipates closing of Pulmatrix, Inc. merger in Q4 subject to customary closing conditions HOUSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Eos SENOLYTIX, Inc. (“Eos” or the “Company”), a biotechnology company developing first-in-class mitochondrial-targeted gerotherapeutics designed to improve body composition, physical function, and metabolic health by targeting the underlying biological mechanisms of aging, today announced that it will present at the 17th World Congress on Targeting Mitochondria 2026, to be held in Berlin from October 21 to 23, 2026.

Kevin Slawin, M.D., Founder and Chief Executive Officer of the Company, will deliver the industry keynote address, “Building on the Foundation of Four: Advancing Mitochondrial-Targeted Geropeptide Medicine.” The address will directly follow the academic keynote scheduled to open the conference, “From Mitochondrial Discovery to Approved Therapy: Lessons for the Future of Medicine,” to be delivered by Dr. Hazel H. Szeto, discoverer of SS-31 (elamipretide), the first U.S. Food and Drug Administration (“FDA”) approved mitochondria-targeted therapeutic.